Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study
- PMID: 36289910
- PMCID: PMC9599330
- DOI: 10.3390/biomedicines10102649
Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study
Abstract
Alpha-synuclein's role in diseases termed "synucleinopathies", including Parkinson's disease, has been well-documented. However, after over 25 years of research, we still do not fully understand the alpha-synuclein protein and its role in disease. In vitro cellular models are some of the most powerful tools that researchers have at their disposal to understand protein function. Advantages include good control over experimental conditions, the possibility for high throughput, and fewer ethical issues when compared to animal models or the attainment of human samples. On the flip side, their major disadvantages are their questionable relevance and lack of a "whole-brain" environment when it comes to modeling human diseases, such as is the case of neurodegenerative disorders. Although now, with the advent of pluripotent stem cells and the ability to create minibrains in a dish, this is changing. With this review, we aim to wade through the recent alpha-synuclein literature to discuss how different cell culture setups (immortalized cell lines, primary neurons, human induced pluripotent stem cells (hiPSCs), blood-brain barrier models, and brain organoids) can help us understand aggregation pathology in Parkinson's and other synucleinopathies.
Keywords: Lewy body; Parkinson’s disease; SH-SY5Y; aggregation; alpha-synuclein; astrocytes; blood–brain barrier; hiPSCs; microglia; mutation; organoid; overexpression; synucleinopathy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Cellular models of alpha-synuclein toxicity and aggregation.J Neurochem. 2019 Sep;150(5):566-576. doi: 10.1111/jnc.14806. Epub 2019 Jul 30. J Neurochem. 2019. PMID: 31265132 Free PMC article. Review.
-
α-synuclein pathogenesis in hiPSC models of Parkinson's disease.Neuronal Signal. 2021 Jun 23;5(2):NS20210021. doi: 10.1042/NS20210021. eCollection 2021 Jun. Neuronal Signal. 2021. PMID: 34239711 Free PMC article. Review.
-
Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders.Life (Basel). 2021 Oct 22;11(11):1126. doi: 10.3390/life11111126. Life (Basel). 2021. PMID: 34833002 Free PMC article. Review.
-
CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.Brain. 2020 Dec 1;143(12):3717-3733. doi: 10.1093/brain/awaa269. Brain. 2020. PMID: 33118032
-
Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation.J Neurosci. 2020 Nov 4;40(45):8618-8628. doi: 10.1523/JNEUROSCI.0954-20.2020. Epub 2020 Oct 12. J Neurosci. 2020. PMID: 33046546 Free PMC article.
Cited by
-
Editorial of the Special Issue: Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease.Biomedicines. 2023 Aug 22;11(9):2330. doi: 10.3390/biomedicines11092330. Biomedicines. 2023. PMID: 37760772 Free PMC article.
-
Structural Specificity of Polymorphic Forms of α-Synuclein Amyloid.Biomedicines. 2023 Apr 29;11(5):1324. doi: 10.3390/biomedicines11051324. Biomedicines. 2023. PMID: 37238996 Free PMC article.
-
Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.Biomolecules. 2023 Aug 18;13(8):1263. doi: 10.3390/biom13081263. Biomolecules. 2023. PMID: 37627328 Free PMC article. Review.
-
Key Connectomes and Synaptic-Compartment-Specific Risk Genes Drive Pathological α-Synuclein Spreading.Adv Sci (Weinh). 2025 Jul;12(25):e2413052. doi: 10.1002/advs.202413052. Epub 2025 May 28. Adv Sci (Weinh). 2025. PMID: 40433888 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources